151 related articles for article (PubMed ID: 38340557)
21. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
22. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Larroquette M; Guegan JP; Besse B; Cousin S; Brunet M; Le Moulec S; Le Loarer F; Rey C; Soria JC; Barlesi F; Bessede A; Scoazec JY; Soubeyran I; Italiano A
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618288
[TBL] [Abstract][Full Text] [Related]
23. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
[TBL] [Abstract][Full Text] [Related]
24. Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer.
An Y; Sun JX; Xu MY; Xu JZ; Ma SY; Liu CQ; Liu Z; Wang SG; Xia QD
Front Immunol; 2022; 13():1049884. PubMed ID: 36420257
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer.
Gao Y; Stein MM; Kase M; Cummings AL; Bharanikumar R; Lau D; Garon EB; Patel SP
Cancer Immunol Immunother; 2023 Feb; 72(2):339-350. PubMed ID: 35881197
[TBL] [Abstract][Full Text] [Related]
26. Identification of a risk score model based on tertiary lymphoid structure-related genes for predicting immunotherapy efficacy in non-small cell lung cancer.
Mei SQ; Liu JQ; Huang ZJ; Luo WC; Peng YL; Chen ZH; Deng Y; Xu CR; Zhou Q
Thorac Cancer; 2024 May; 15(14):1119-1131. PubMed ID: 38558529
[TBL] [Abstract][Full Text] [Related]
27. Combined inflammatory parameters and tertiary lymphoid structure predict prognosis in patients with resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Xu F; Zhu H; Dong Y; Li L; Liu N; Yuan S
Front Immunol; 2023; 14():1244256. PubMed ID: 38155965
[TBL] [Abstract][Full Text] [Related]
28. A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.
Jiang Z; Zhou Y; Huang J
Front Immunol; 2021; 12():813331. PubMed ID: 35003141
[TBL] [Abstract][Full Text] [Related]
29. HLA-A
Zhang D; Jiang D; Jiang L; Ma J; Wang X; Xu X; Chen Z; Jiang M; Ye W; Wang J; Meng W; Qiu W; Hou Y; Huang J; Jiao Y; Liu Y; Liu Z
Br J Cancer; 2024 May; ():. PubMed ID: 38762674
[TBL] [Abstract][Full Text] [Related]
30. The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective study.
Fukuhara M; Muto S; Inomata S; Yamaguchi H; Mine H; Takagi H; Ozaki Y; Watanabe M; Inoue T; Yamaura T; Okabe N; Matsumura Y; Hasegawa T; Osugi J; Hoshino M; Higuchi M; Shio Y; Suzuki H
Cancer Immunol Immunother; 2022 May; 71(5):1129-1137. PubMed ID: 34596720
[TBL] [Abstract][Full Text] [Related]
31. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines.
Di Modugno F; DeMonte L; Balsamo M; Bronzi G; Nicotra MR; Alessio M; Jager E; Condeelis JS; Santoni A; Natali PG; Nisticò P
Cancer Res; 2007 Mar; 67(6):2657-65. PubMed ID: 17363586
[TBL] [Abstract][Full Text] [Related]
32. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer.
J Gunderson A; Rajamanickam V; Bui C; Bernard B; Pucilowska J; Ballesteros-Merino C; Schmidt M; McCarty K; Philips M; Piening B; Dubay C; Medler T; Newell P; Hansen P; Tran E; Tang E; Bifulco C; Crittenden M; Gough M; Young KH
Oncoimmunology; 2021 Mar; 10(1):1900635. PubMed ID: 33796412
[TBL] [Abstract][Full Text] [Related]
33. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
Xu F; Zhu H; Xiong D; Wang K; Dong Y; Li L; Yuan S
Thorac Cancer; 2024 Jan; 15(2):172-181. PubMed ID: 38057283
[TBL] [Abstract][Full Text] [Related]
34. Tertiary Lymphoid Structure Raises Survival and Immunotherapy in HPV
Li H; Zhu SW; Zhou JJ; Chen DR; Liu J; Wu ZZ; Wang WY; Zhang MJ; Sun ZJ
J Dent Res; 2023 Jun; 102(6):678-688. PubMed ID: 36883630
[TBL] [Abstract][Full Text] [Related]
35. Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC.
Wang S; Fan G; Li L; He Y; Lou N; Xie T; Dai L; Gao R; Yang M; Shi Y; Han X
Cancer Immunol Immunother; 2023 Jul; 72(7):2423-2442. PubMed ID: 37010552
[TBL] [Abstract][Full Text] [Related]
36. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
[TBL] [Abstract][Full Text] [Related]
37. Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma.
Liu Z; Meng X; Tang X; Zou W; He Y
Cancer Immunol Immunother; 2023 Jun; 72(6):1505-1521. PubMed ID: 36481914
[TBL] [Abstract][Full Text] [Related]
38. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.
Shao XM; Huang J; Niknafs N; Balan A; Cherry C; White J; Velculescu VE; Anagnostou V; Karchin R
Ann Oncol; 2022 Jul; 33(7):728-738. PubMed ID: 35339648
[TBL] [Abstract][Full Text] [Related]
39. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts.
Rodriguez AB; Peske JD; Woods AN; Leick KM; Mauldin IS; Meneveau MO; Young SJ; Lindsay RS; Melssen MM; Cyranowski S; Parriott G; Conaway MR; Fu YX; Slingluff CL; Engelhard VH
Cell Rep; 2021 Jul; 36(3):109422. PubMed ID: 34289373
[TBL] [Abstract][Full Text] [Related]
40. HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC.
Mei J; Jiang G; Chen Y; Xu Y; Wan Y; Chen R; Liu F; Mao W; Zheng M; Xu J
BMC Cancer; 2022 Jul; 22(1):738. PubMed ID: 35794593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]